Table 1. Clinical characteristics of the study groups.
| Placebo (n = 20) |
Coenzyme Q10 (n = 20) |
Combined antioxidant therapy (n = 20) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Final | P | Baseline | Final | P | Baseline | Final | P | P | ||
| WCX | WCX | WCX | K–W | ||||||||
| Gender (male/female) | % | (9/11) | – | (11/ 9) | – | (10/11) | – | – | |||
| Age | Years | 57.8 ± 1.9 | – | 58.5 ± 1.9 | – | 62.1 ± 1.1 | – | NS | |||
| DM type 2 evolution | Years | 14.2 ± 1.3 | 14.2 ± 1.3 | – | 15.4 ± 1.6 | 15.4 ± 1.6 | – | 15.2 ± 1.3 | 15.2 ± 1.3 | – | NS |
| Body mass index (BMI) | kg/m2 | 29.3 ± 0.8 | 29.2 ± 0.9 | NS | 28.2 ± 3.7 | 28.5 ± 0.9 | NS | 28.6 ± 4.5 | 29.2 ± 0.9 | NS | NS |
| Systolic arterial pressure (SAP) | mmHg | 128.4 ± 1.3 | 129.5 ± 2.7 | NS | 131.4 ± 19.4 | 132.4 ± 3.2 | NS | 144.5 ± 15.8 | 135.8 ± 3.5 | NS | NS |
| Diastolic arterial pressure (DAP) | mmHg | 74.0 ± 1.1 | 75.1 ± 2.0 | NS | 80.7 ± 10.8 | 73.4 ± 2.7 | NS | 84.8 ± 7.2 | 74.9 ± 2.8 | NS | NS |
| Left eye pressure (LEP) | mmHg | 14.9 ± 2.1 | 14.8 ± 0.6 | NS | 15.4 ± 1.1 | 15.2 ± 0.5 | NS | 15.3 ± 0.9 | 14.7 ± 0.9 | NS | NS |
| Corrected visual acuity (CVA) | 6 m | 0.9 ± 0.0 | 0.9 ± 0.0 | NS | 0.8 ± 0.0 | 0.8 ± 0.0 | NS | 0.8 ± 0.1 | 0.8 ± 0.1 | NS | NS |
The table illustrates the metabolic profile per study group, where values are expressed as mean ± standard error. The three groups were homogeneous. The P-value was calculated with the Wilcoxon and Kruskal–Wallis tests, with no significant differences.